

# Screening for precapillary pulmonary hypertension in chronic myeloproliferative disorders: the role of N-terminal pro-B-type natriuretic peptide and vascular endothelial growth factor – a pilot study

Gyöngyvér Költő<sup>1</sup>, Margit Tókécs-Füzesi<sup>2</sup>, Előd Papp<sup>1,3</sup>, Zsófia Adravetz<sup>4</sup>, András Komócsi<sup>4</sup>, Miklós Egyed<sup>5</sup>, Réka Faludi<sup>4</sup>

<sup>1</sup>Department of Cardiology, Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary

<sup>2</sup>Department of Laboratory Medicine, Medical School, University of Pécs, Pécs, Hungary

<sup>3</sup>Department of Internal Medicine, Szent Lukács Hospital, Dombóvár, Hungary

<sup>4</sup>Heart Institute, Medical School, University of Pécs, Pécs, Hungary

<sup>5</sup>Department of Hematology, Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary

**Submitted:** 29 July 2019

**Accepted:** 31 December 2018

Arch Med Sci

DOI: <https://doi.org/10.5114/aoms.2020.93315>

Copyright © 2020 Termedia & Banach

## Corresponding author:

Réka Faludi MD, PhD

Heart Institute

University of Pécs

H-7624, Pécs, Ifjúság 13

Hungary

Phone: +3672536000

Fax: +3672536388

E-mail: [faludi.reka@pte.hu](mailto:faludi.reka@pte.hu)

## Abstract

**Introduction:** Precapillary pulmonary hypertension (PH) implies a worse prognosis in myeloproliferative neoplasms (MPN). N-terminal pro-B-type natriuretic peptide (NT-proBNP) is elevated in cardiopulmonary involvement. In MPN patients with precapillary PH, elevated vascular endothelial growth factor (VEGF) values, but in left heart (LH) disease patients, decreased values were reported. Our aim was to determine whether a combination of NT-proBNP and VEGF is suitable for the detection of the precapillary forms of PH in MPN patients.

**Material and methods:** Eighty-one MPN patients were investigated. Pulmonary hypertension was defined as Doppler-derived systolic pulmonary artery pressure (sPAP)  $\geq 40$  mm Hg. Patient groups with cardiopulmonary involvement (precapillary PH, PH due to LH disease, left ventricular ejection fraction  $< 50\%$ , atrial fibrillation) or LH disease (PH due to LH disease, left ventricular ejection fraction  $< 50\%$ , atrial fibrillation) were identified.

**Results:** In nine patients PH was associated with LH disease. In two patients precapillary PH was found with extremely high NT-proBNP values. NT-proBNP significantly correlated with sPAP ( $r = 0.550$ ;  $p < 0.001$ ). NT-proBNP  $\geq 466$  pg/ml was the best predictor of cardiopulmonary involvement (AUC: 0.962, sensitivity: 86.7%, specificity: 93.9%). No correlation was found between VEGF levels and sPAP values. VEGF  $\leq 431$  pg/ml was the best predictor of LH disease (AUC: 0.609, sensitivity: 76.9%, specificity: 62.7%).

**Conclusions:** NT-proBNP levels reflect cardiopulmonary involvement with high accuracy, but the combination of NT-proBNP and VEGF is not suitable for the detection of precapillary PH as the diagnostic power of VEGF is limited. Highly elevated NT-proBNP levels may suggest precapillary PH but further investigation is necessary for the exclusion of LH disease or atrial fibrillation.

**Key words:** pulmonary hypertension, myeloproliferative neoplasms, NT-proBNP, vascular endothelial growth factor, screening.

## Introduction

A sub-group of myeloproliferative neoplasms (MPN) is BCR-ABL1-negative MPN that includes polycythemia vera, essential thrombocythemia, and primary myelofibrosis [1]. These disorders are characterized by stem cell-derived clonal myeloproliferation. Although the association between MPN and precapillary pulmonary hypertension (PH) has been suggested by case reports and small series, the exact prevalence of pulmonary vascular abnormalities in myeloid diseases is currently not known [2–9]. Pulmonary hypertension represents a heterogeneous group of disorders that are classified based on differences in clinical, hemodynamic, and histopathologic features. In the general population the most common forms of PH are associated with left heart (LH) disease (Group 2) or with pulmonary diseases (Group 3). Pulmonary arterial hypertension (PAH – Group 1) is a progressive disorder characterized by remodelling of the small pulmonary arteries, resulting in increased pulmonary vascular resistance [10]. In the context of MPN, typical forms of PH are chronic thromboembolic PH (CTEPH – Group 4), drug-induced PH, and a characteristic precapillary PH with multifactorial origin (Group 5). The latter form may mimic Group 1 PAH [10, 11]. Pulmonary hypertension due to LH disease is classified as postcapillary as it is characterized by elevated left ventricular filling pressure. The other groups comprise precapillary or mixed PH-forms. Treatment of PH is strictly determined by the type of the disease. If it is caused by LH disease or lung diseases, our choice is to optimize the therapy of the underlying condition. Group 2 and 3 patients should not routinely be treated with vasoactive agents approved for the treatment of PAH [10]. A modified version of the current classification of PH and group-specific treatment options are reported in Table I [10].

Once precapillary PH is diagnosed, the prognosis of MPN patients is unfavourable [7, 8]. Echocardiography enables a clinically satisfactory differential diagnosis between pre- and postcapillary PH [12, 13]. As primary screening tool, however, echocardiography is not feasible due to its limited availability and high cost. For this reason, there is a need for reliable biomarkers for screening of precapillary PH in MPN patients. *N*-terminal pro-B-type natriuretic peptide (NT-proBNP) is a useful but not specific marker of right ventricular dysfunction of PH patients [14–16] as its level is also elevated in patients with LH failure [17] and/or atrial fibrillation [18, 19]. Vascular endothelial growth factor (VEGF) – one of the signal proteins stimulating angiogenesis – may be another potential biomarker as its elevated serum levels have been reported in patients with idiopathic PAH [20, 21]. On the other hand, decreased VEGF values have been reported in patients with

LH disease [22, 23]. In addition, VEGF is believed to contribute to the pathogenesis of MPN [24] and it has also been suggested that VEGF may play a causative role in induction of Group 5 precapillary PH in MPN patients [5, 25].

Thus the aim of this study was to determine whether combined use of NT-proBNP and VEGF as biomarkers is suitable for the detection of the precapillary forms of PH in a large MPN population.

## Material and methods

### Patients

Outpatients with MPN were consecutively screened into this prospective cohort study during a seven-month period in the Department of Haematology, Somogy County Kaposi Mór Teaching Hospital. Considered as a pilot study, a convenient sample size of 90 patients was chosen. Inclusion criteria were: diagnosis of MPN based on the current algorithms [1], age  $\geq 18$  years, capacity to give informed consent, stable disease (no transformation into acute myeloid leukaemia). Exclusion criteria were: refusal to give informed consent, poor echo window. Baseline clinical (age, gender, body mass index [BMI], JAK2 positivity) and laboratory (blood count, estimated glomerular filtration rate [eGFR], uric acid level) data, as well as data about medication and co-morbidities were collected. The study complied with the Declaration of Helsinki. The institutional ethics committee approved the study. Informed consent was obtained from all individual participants included in the study.

### Echocardiography

12-lead surface electrocardiogram (ECG) was obtained to diagnose atrial fibrillation. Echocardiography was performed using the Philips IE330 ultrasound system (Philips Healthcare, Best, The Netherlands) by a single investigator. Left ventricular ejection fraction was measured by biplane Simpson's method. Left ventricular mass was calculated according to the Devereux formula. As a parameter of right ventricular systolic function, tricuspid annular plane systolic excursion (TAPSE) was measured [26]. In addition to the parameters of mitral inflow (peak of the early [E] and late [A] diastolic velocities), myocardial early (e') diastolic velocities were measured at the lateral and septal border of the mitral annulus by pulsed tissue Doppler. Lateral and septal e' values were averaged. Mitral E/A and E/e' ratios were calculated. Left ventricular diastolic function as well as severity of the aortic, mitral, and tricuspid regurgitations were classified according to the current recommendations [27, 28]. Systolic pulmonary artery pressure (sPAP) was estimated as the sum of the pressure difference across the tricuspid

**Table I.** Modified version of the current classification of pulmonary hypertension (PH) [10]. Group-specific treatment options are also presented. Type and number of PH cases found in our myeloproliferative neoplasms population are formatted in bold (\*The definition of heart failure with mid-range left ventricular ejection fraction was first reported in the literature in 2016 [17]; therefore it is not mentioned in the recent PH guideline.)

Group	Sub-groups	Treatment
1 – Pulmonary arterial hypertension	Idiopathic Heritable Drug and toxin induced Associated with: – Connective tissue disease – HIV – Portal hypertension – Congenital heart disease – Schistosomiasis	Specific vasodilator drugs: – Endothelin receptor antagonists – Phosphodiesterase-5 inhibitors – Soluble guanylate cyclase stimulators – Selective prostacyclin receptor agonists – Prostacyclins
2 – Pulmonary hypertension due to left heart disease	Heart failure with reduced ejection fraction <b>Heart failure with preserved ejection fraction (n = 8)</b> <b>Heart failure with mid-range ejection fraction (n = 1)*</b> Valvular disease Etc.	Treatment of the underlying heart disease
3 – Pulmonary hypertension due to lung diseases and/or hypoxia	Chronic obstructive pulmonary disease Interstitial lung disease Sleep-disordered breathing Etc.	Treatment of the underlying lung disease
<b>4 – Chronic thromboembolic pulmonary hypertension (n = 1)</b>	–	Surgical: pulmonary endarterectomy In inoperable or persisting cases: specific vasodilator drugs
5 – Pulmonary hypertension with unclear and/or multifactorial mechanisms	Haematological disorders: – Chronic haemolytic anaemia – <b>Myeloproliferative disorders (n = 1)</b> – Splenectomy Systemic disorders: – Sarcoidosis – Etc. Metabolic disorders: – Glycogen storage disease – Gaucher disease – Thyroid disorders Others	Treatment of the underlying disease Specific vasodilator drugs may be useful in precapillary forms

valve calculated using the modified Bernoulli equation and an estimate of mean right atrial pressure using the diameter and the collapsibility index of the inferior vena cava (IVC) (5 mm Hg if IVC  $\leq$  21 mm and collapse with sniff  $>$  50%; 15 mm Hg if IVC  $>$  21 mm and collapse with sniff  $<$  50%; 10 mm Hg at intermediate values) [29]. Pulmonary hypertension was defined as Doppler-derived sPAP  $\geq$  40 mm Hg. Differential diagnosis between pre- and postcapillary PH was based on echocardiographic data. Characteristics of the precapillary PH were as follows: dilated right heart, systolo-diastolic D-sign, dilated IVC without inspiratory collapse, left ventricular E/e'  $<$  10 [11].

#### NT-proBNP and VEGF assays

Blood samples were collected on the day of the echocardiography. Analysis of plasma VEGF levels

was performed using human VEGF-A Platinum ELISA kit (eBioscience, San Diego, CA, USA). NT-proBNP was measured using electrochemiluminescence immunoassay on the Elecsys 2010 system (Roche Diagnostics, Mannheim, Germany).

#### Statistical analysis

Continuous variables are presented as mean  $\pm$  SD. Categorical variables are expressed as frequencies and percentages. Comparisons between groups were performed using the independent Mann-Whitney test for NT-proBNP and VEGF levels. Since NT-proBNP and VEGF values did not show a normal distribution, logarithmic transformation was performed (lnNT-proBNP, lnVEGF). Clinical variables that correlate with NT-proBNP and VEGF levels were determined using bivariate Pearson correlation. Receiver-operating charac-

**Table II.** Clinical and echocardiographic data of the myeloproliferative neoplasms (MPN) patients and their correlations with NT-proBNP (ln)

Factor	MPN patients (n = 81)	Correlation with NT-proBNP (ln)	
		r	P
Age [years]	67.1 ±12.5	0.509	<b>&lt; 0.001</b>
Female gender, n (%)	51 (63)	0.130	0.248
Body mass index [kg/m <sup>2</sup> ]	27 ±5	−0.213	0.155
JAK2 positivity, n (%)	66 (81.5)	0.020	0.862
Disease duration [years]	6.2 ±4.5	0.048	0.670
Splenomegaly, n (%)	14 (17)	0.120	0.284
Recent smoker, n (%)	11 (14)	0.112	0.318
Laboratory data			
Haemoglobin [g/l]	138.4 ±19.6	−0.263	<b>0.018</b>
White blood cells [10 <sup>9</sup> /l]	8.6 ±3.4	0.016	0.891
Platelet [10 <sup>9</sup> /l]	427.1 ±207.6	−0.130	0.246
eGFR [ml/min/1.73 m <sup>2</sup> ]	70.3 ±19.9	−0.515	<b>&lt; 0.001</b>
Uric acid [μmol/l]	339.4 ±82.2	0.378	<b>0.001</b>
NT-proBNP [pg/ml]	532.1 ±1195.1	–	
VEGF [pg/ml]	789.0 ±737.6	−0.021	0.855*
Medication			
Acetylsalicylic acid, n (%)	55 (68)	−0.123	0.274
Hydroxyurea, n (%)	69 (85)	0.075	0.506
Anagrelide, n (%)	17 (21)	0.056	0.617
PEG-IFN-2α, n (%)	15 (19)	0.104	0.356
Ruxolitinib, n (%)	4 (5)	0.015	0.892
Co-morbidities			
History of thromboembolic event, n (%)	19 (23)	0.036	0.753
Systemic hypertension, n (%)	58 (72)	0.017	0.883
Diabetes, n (%)	12 (15)	0.035	0.755
Atrial fibrillation, n (%)	7 (9)	0.414	<b>&lt; 0.001</b>
Echocardiographic data			
LV ejection fraction (%)	62.5 ±6.6	−0.325	<b>0.004</b>
sPAP [mm Hg]	32.8 ±10.9	0.550	<b>&lt; 0.001</b>
E/A	0.8 ±0.3	−0.397	<b>0.001</b>
Left ventricular mass [g]	222 ±59.3	0.163	0.146
Mitral regurgitation (mild: moderate: severe), n	36 : 19 : 5	0.329	<b>0.036</b>
Tricuspid regurgitation (mild: moderate: severe), n	48 : 14 : 2	0.349	<b>0.004</b>
Aortic regurgitation (mild: moderate: severe), n	16 : 5 : 0	0.082	0.723
TAPSE [mm]	27.4 ±3.6	−0.402	<b>&lt; 0.001</b>
Average mitral annular e' [cm/s]	7.5 ±2.6	−0.314	<b>0.014</b>
Mitral E/e'	9.7 ±3.8	0.310	<b>0.016</b>
IVC [mm]	19.9 ±3.7	0.031	0.919

Statistically significant p-values ( $p < 0.05$ ) are formatted in bold. \*Correlation between lnVEGF and lnNT-proBNP. eGFR – estimated glomerular filtration rate, PEG-INF – pegylated interferon, LV – left ventricular, sPAP – systolic pulmonary artery pressure, TAPSE – tricuspid annular plane systolic excursion, IVC – inferior vena cava.

teristic (ROC) curve analysis was used to examine the performance of NT-proBNP in predicting cardiopulmonary involvement (precapillary PH, PH due to LH disease, left ventricular ejection fraction < 50%, atrial fibrillation) and the performance of VEGF in predicting LH disease (PH due to LH disease, left ventricular ejection fraction < 50%, atrial fibrillation). The latter analysis was repeated using the ratio of serum VEGF to platelet count as a biomarker [31]. Optimal cut-off values were chosen to maximize sensitivity and specificity. A *p* value of < 0.05 was considered significant. Data were analysed using SPSS 22.0 statistical software (SPSS, Chicago, Illinois).

## Results

Ninety consecutive patients were evaluated for inclusion. After exclusion of 9 patients (2 refused to sign the informed consent; in one patient MPN transformed to overt acute myeloid leukaemia and in 6 patients echocardiographic data could not be obtained due to unfavourable thoracic anatomy) 81 patients were enrolled in the study – 39 (48%), 39 (48%) and 3 (4%) patients had essential thrombocytosis, polycythemia vera and primary myelofibrosis, respectively. Clinical and laboratory data of the 81 patients are outlined in Table II.

In 4 (5%) patients moderately reduced (35–50%) left ventricular ejection fraction was found. Further echocardiographic data are reported in Table II.

Pulmonary hypertension was diagnosed in 11 (13.6%) cases (Table I): In 8 patients PH was associated with heart failure with preserved left ventricular ejection fraction (HFpEF) while in 1 patient it was associated with heart failure with mid-range left ventricular ejection fraction (HFmrEF). Two (2.5%) patients showed the typical signs of precapillary PH, so they underwent further investigation. In the first patient, pulmonary embolism and lung parenchyma diseases were excluded. Precapillary PH (Group 5) was diagnosed. In the second patient clear evidence of CTEPH was found. Detailed characteristics of these patients are outlined in Table III.

Atrial fibrillation was found in 7 (9%) patients, including the patient with HFmrEF-PH and 3 of those with HFpEF-PH.

NT-proBNP levels significantly correlated with the non-invasively measured sPAP values, and with several other clinical and echocardiographic parameters (Table II). Significantly higher NT-proBNP values were found in patients with cardiopulmonary involvement (left ventricular ejection fraction < 50%, PH due to LH disease, precapillary PH, atrial fibrillation; *n* = 15) than in the other MPN patients ( $1891.5 \pm 2214.6$  vs.  $223.1 \pm 422.2$  pg/ml; *p* < 0.001). Extremely high NT-proBNP values were found in both patients with precapillary PH

(Table III). Using ROC analysis, NT-proBNP  $\geq 466$  pg/ml was the best predictor of cardiopulmonary involvement (AUC: 0.962, sensitivity: 86.7%, specificity: 93.9%).

No correlation was found between VEGF levels and sPAP values. Among all clinical and echocardiographic parameters, VEGF levels showed a significant correlation only with platelet number (*r* = 0.277, *p* = 0.014). VEGF values were lower in patients with LH disease (left ventricular ejection fraction < 50%, PH due to LH disease, atrial fibrillation; *n* = 13) compared with the rest of the population ( $534.7 \pm 676.0$  vs.  $823.1 \pm 738.6$  pg/ml; *p* = 0.214), but the difference was not statistically significant. Using ROC analysis, VEGF  $\leq 431$  pg/ml was the best predictor of LH disease (AUC: 0.609, sensitivity: 76.9%, specificity: 62.7%). VEGF level was higher in our Group 5 patient, while it was lower in our CTEPH patient than this cut-off value (Table III). The diagnostic performance of the test improved only mildly if the ratio of serum VEGF to platelet count was used as a biomarker (AUC: 0.641).

## Discussion

The possible association between precapillary PH and MPN has been suggested by case reports and small case series [2–9]. Nevertheless, the exact prevalence and incidence of the pulmonary vascular involvement are unknown in this disease. In the study of Chebrek *et al.* low prevalence of precapillary PH was observed (less than 5%) in MPN patients [32]. This result is quite different from that given by analysis of data from the previous literature, which revealed a global prevalence of 38% [2–5]. This discrepancy may have different explanations. First, the small size of the series reported may represent a bias in the study. In addition, the rate of precapillary PH may be greatly overestimated by echocardiography without careful elimination of patients with left ventricular dysfunction.

Due to its restricted size and the single-centre design, our study was not adequately powered to assess the prevalence of precapillary PH in MPN patients. Our data suggest, however, that PH due to LH disease is relatively common in this elderly, multimorbid population while precapillary forms of PH are less frequent.

Three major distinct clinical forms of PH have been described in patients with MPN: CTEPH, drug-induced PH and precapillary PH with multifactorial origin (Group 5). Although MPN – especially polycythemia vera and essential thrombocytosis – is a thrombophilic state, the epidemiological and clinical data on CTEPH in MPN patients are scarce. In their retrospective study Guilpan *et al.* reported six MPN patients with CTEPH. Interestingly, the



Table III. Detailed characteristics of our myeloproliferative neoplasms patients with precapillary pulmonary hypertension

No.	Age, gender	Type of MPN	Disease duration	ECHO derived sPAP	ECG	NT-proBNP (pg/ml)	VEGF (pg/ml)	Type of PH	RHC	Specific treatment for PH	Survival after PH diagnosis
1	68 years, female	ET	5 years	90 mm Hg	Sinus rhythm RBBB	5910	889	Precapillary (Group 5)	Mean PAP: 63 mm Hg PAWP: 8 mm Hg CO: 2.2 l/min PVR: 25 Wood	Tadalafil, macitentan	28 months, living
2	71 years, male	PV	9 years	71 mm Hg	Sinus rhythm RBBB	7847	138	CTEPH	Refused	Refused	6 months, deceased

sPAP – systolic pulmonary artery pressure, RHC – right heart catheterization, PH – pulmonary hypertension, ET – essential thrombocythemia, PV – polycythemia vera, HU – hydroxyurea, RBBB – right bundle branch block, CTEPH – chronic thromboembolic pulmonary hypertension, PAWP – pulmonary artery wedge pressure, CO – cardiac output, PVR – pulmonary vascular resistance.

diagnosis of CTEPH and MPN was made simultaneously in all patients, suggesting that CTEPH may be the first manifestation of the myeloproliferative diseases [6].

Several factors may contribute to precapillary (Group 5) PH in MPN. One possible explanation for the pathogenesis of PH is enhanced angiogenesis [21]. Group 5-PH is usually diagnosed late: 8-13.5 years after the recognition of the myeloproliferative disorder [6, 7]. The effectiveness of PAH-specific vasodilator therapy has not been proven yet in MPN. The prognosis is poor; the median time to death is 18 months after the diagnosis [8].

Tyrosine kinase inhibitors are used as a therapy for chronic myeloid leukaemia. Several case reports have suggested that PH may be one of the potential complications of dasatinib. Although a few patients have experienced full clinical and haemodynamic recovery after discontinuation of dasatinib, the majority have not recovered completely [33].

In our study, two patients showed clear signs of precapillary PH. Dasatinib use was not documented in these patients. Unfortunately our CTEPH patient refused invasive evaluation and further treatment and died within 6 months. In our Group 5-PH patient combined pulmonary vasodilator treatment was introduced. 28 months later the patient is still alive, in a New York Heart Association II–III functional status. Her history suggests that the use of the PAH-specific vasodilator drugs is worth further investigation in Group 5-PH patients.

Although according to the guidelines the final diagnosis of precapillary PH requires right heart catheterization (RHC), echocardiography is able to differentiate between post- and precapillary PH with good accuracy [12, 13]. Nevertheless, as a primary screening tool, the use of biomarkers seems to be more feasible. Thus we aimed to evaluate whether combined use of two biomarkers – NT-proBNP and VEGF – is suitable for detection of the precapillary forms of PH in MPN patients.

NT-proBNP is a neurohormone secreted mainly in the cardiac ventricles in response to volume expansion or pressure overload. Its prognostic power has been reported in various conditions [34, 35]. Its diagnostic and prognostic value was also proved in PH [16, 36]. In special populations with high risk for the development of PAH, NT-proBNP has been suggested as a sensitive biomarker for screening [37, 38]. Nevertheless, elevated NT-proBNP is not specific for right-sided heart disease, as its level is also elevated in patients with LH failure [17] and/or atrial fibrillation [18, 19]. Several other confounding factors may also raise the level of this biomarker: advanced age, anaemia, or renal dysfunction [39, 40]. Despite the well recognizable effects of these factors, NT-proBNP showed good diagnostic performance in identifying patients with manifested cardiopulmo-

nary involvement in our study. It is of note that especially high NT-proBNP values were found in both patients with precapillary PH. Still, MPN patients with elevated NT-proBNP values require further investigation (ECG and echocardiography) to identify the type of their cardiopulmonary involvement.

VEGF plays a critical role in angiogenesis due to its ability to regulate proliferation, migration, specialisation and survival of endothelial cells [41]. In bone marrow of BCR-ABL1-negative MPN patients increased microvessel density and VEGF expression were reported [42, 43]. Furthermore, VEGF has been reported to be a key contributor to angiogenesis and vasculogenesis in idiopathic PAH, where elevated pulmonary artery pressure is the consequence of vasoconstriction and remodelling of pulmonary microvasculature [20, 21, 44]. Similarly, VEGF may play a causative role in induction of Group 5 PH in MPN patients [6, 25]. Data about the VEGF level of CTEPH patients are contradictory [20, 21], while decreased VEGF values have been reported in patients with LH disease [22, 23]. In our study VEGF showed a clear tendency to be lower in patients with LH disease than in the rest of the population. Our results suggest, however, that VEGF is not a suitable screening tool for this purpose due to its moderate sensitivity and low specificity. The correlation between VEGF level and platelet count has already been reported in the literature [45, 46]; thus the actual platelet count may affect the diagnostic abilities of this biomarker. Nevertheless, the use of the ratio of serum VEGF to platelet count did not improve the diagnostic performance substantially in our study. Similarly to the results of Suzuki *et al.* [20], a low VEGF value was found in our CTEPH patient. The high VEGF level of our Group 5 PH patient is in line with the results of Cortelezzi *et al.* [5]. Further studies are required involving numerous MPN patients with Group 5 PH to investigate whether VEGF plays a central role in the pathogenesis of this special condition.

Some limitations of our study are to be acknowledged. First of all, due to its restricted sample size the correlations between biomarkers and other variables may be misclassified.

Due to the lack of a healthy control group we could not define the cut-off value between normal and elevated/reduced VEGF levels.

Although severe precapillary PH is rare in chronic obstructive pulmonary disease (COPD) [47] and elevation of natriuretic peptide levels is typically mild [48], presence of COPD may influence the NT-proBNP level of the patients. In addition, COPD may have an impact on the VEGF levels [49]. Pulmonological data, however, were not available in our MPN population.

Several confounding factors may influence the velocity of the tricuspid regurgitation, includ-

ing anaemia and consequential high cardiac output; therefore RHC may be mandatory for the correct diagnosis and classification of PH. In our study, however, RHC was performed in only one of the patients with precapillary PH.

In conclusion, NT-proBNP levels reflected cardiopulmonary involvement with high accuracy, but the combination of NT-proBNP and VEGF was not suitable for detection of the precapillary PH in our MPN population, as the diagnostic power of VEGF was limited. Highly elevated NT-proBNP levels may suggest precapillary PH, but further investigation is necessary for the exclusion of LH disease and/or atrial fibrillation.

## Conflict of interest

The authors declare no conflict of interest.

## References

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. *Leukemia* 2008; 22: 14-22.
2. Garypidou V, Vakalopoulou S, Dimitriadis D, Tziomalos K, Sfikas G, Perifanis V. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. *Haematologica* 2004; 89: 245-6.
3. Altintas A, Karahan Z, Pasa S, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. *Leuk Lymphoma* 2007; 48: 1981-7.
4. Gupta R, Perumandla S, Patsiornik Y, Niranjana S, Ohri A. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. *J Natl Med Assoc* 2006; 98: 1779-82.
5. Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. *Leukemia* 2008; 22: 646-9.
6. Guilpain P, Montani D, Damaj G, et al. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. *Respiration* 2008; 76: 295-302.
7. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. *Chest* 2001; 120: 801-8.
8. Garcia-Manero G, Schuster SJ, Patrick H, Martinez J. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. *Am J Hematol* 1999; 60: 130-5.
9. Ziakas PD, Voulgarelis M, Felekouras E, Anagnostou D, Tzelepis GE. Myelofibrosis-associated massive splenomegaly: a cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. *Am J Hematol* 2005; 80: 128-32.
10. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. *Eur Heart J* 2016; 37: 67-119.
11. Adir Y, Elia D, Harari S. Pulmonary hypertension in patients with chronic myeloproliferative disorders. *Eur Respir Rev* 2015; 24: 400-10.
12. D'Alto M, Romeo E, Argiento P, et al. Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. *J Am Soc Echocardiogr* 2015; 28: 108-15.

13. Opatowsky AR, Ojeda J, Rogers F, et al. A simple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. *Circ Cardiovasc Imaging* 2012; 5: 765-775.
14. Gan CT, McCann GP, Marcus JT, et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension. *Eur Respir J* 2006; 28: 1190-4.
15. Casserly B, Klinger JR. Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent. *Drug Des Devel Ther* 2009; 3: 269-87.
16. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. *J Cardiol* 2001; 37: 110-1.
17. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur J Heart Fail* 2016; 18: 891-975.
18. Corell P, Gustafsson F, Kistorp C, Madsen LH, Schou M, Hildebrandt P. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. *Int J Cardiol* 2007; 117: 395-402.
19. Asselbergs FW, van den Berg MP, Bakker SJ, et al. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort. *Neth Heart J* 2008; 16: 73-8.
20. Suzuki S, Yoshihisa A, Yokokawa T, et al. Association between levels of anti-angiogenic isoform of vascular endothelial growth factor A and pulmonary hypertension. *Int J Cardiol* 2016; 222: 416-20.
21. Säleby J, Bouzina H, Lundgren J, Rådegran G. Angiogenic and inflammatory biomarkers in the differentiation of pulmonary hypertension. *Scand Cardiovasc J* 2017; 51: 261-70.
22. Arakawa H, U Ikeda, Y Hojo, et al. Decreased serum vascular endothelial growth factor concentrations in patients with congestive heart failure. *Heart* 2003; 89: 207-8.
23. Patel JV, Abraheem A, Chackathayil J, et al. Circulating biomarkers of angiogenesis as indicators of left ventricular systolic dysfunction amongst patients with coronary artery disease. *J Intern Med* 2009; 265: 562-7.
24. Boiocchi L, Vener C, Savi F, et al. Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms. *J Clin Pathol* 2011; 64: 226-31.
25. Adir Y, Humbert M. Pulmonary hypertension in patients with chronic myeloproliferative disorders. *Eur Respir J* 2010; 35: 1396-406.
26. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults. *Eur Heart J Cardiovasc Imaging* 2015; 16: 233-70.
27. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. *Eur Heart J Cardiovasc Imaging* 2016; 17: 1321-60.
28. Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation. *Eur Heart J Cardiovasc Imaging* 2013; 14: 611-44.
29. Rudski LG, Lai WW, Afilalo J, et al. Guidelines for the echocardiographic assessment of the right heart in adults. *J Am Soc Echocardiogr* 2010; 23: 685-713.
30. D'Alto M, Romeo E, Argiento P, et al. Echocardiographic prediction of pre- versus postcapillary pulmonary hypertension. *J Am Soc Echocardiogr* 2015; 28: 108-15.
31. Koga H, Tokunaga Y, Hisamoto T, et al. Ratio of serum vascular endothelial growth factor to platelet count correlates with disease activity in a patient with POEMS syndrome. *Eur J Intern Med* 2002; 13: 70-74.
32. Chebrek S, Aissi K, Frances Y, et al. Pulmonary hypertension in patients with chronic myeloproliferative neoplasms. *Leuk Lymphoma* 2014; 55: 223-5.
33. Orlandi EM, Rocca B, Pazzano AS, Ghio S. Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukaemia. *Leuk Res* 2012; 36: e4-6.
34. Költő G, Vuolteenaho O, Szokodi I, et al. Prognostic value of N-terminal natriuretic peptides in systemic sclerosis: a single centre study. *Clin Exp Rheumatol* 2014; 32 (6 Suppl 86): S-75-81.
35. Ozcan N, Ozcan A, Kaymak C, et al. Comparison of prognostic value of N-terminal pro-brain natriuretic peptide in septic and non-septic intensive care patients. *Arch Med Sci* 2017; 13: 418-25.
36. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. *Eur Respir J* 2007; 29: 737-44.
37. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. *Arthritis Res Ther* 2012; 14: R143.
38. Chung L, Fairchild RM, Furst DE, et al. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry. *Clin Exp Rheumatol* 2017; 35: 106-13.
39. Hogenhuis J, Voors AA, Jaarsma T, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. *Eur J Heart Fail* 2007; 9: 787-94.
40. Curiati MN, Silvestre OM, Pires LJ, et al. Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables. *Einstein (Sao Paulo)* 2013; 11: 273-7.
41. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. *Pharmacol Rev* 2004; 56: 549-80.
42. Medinger M, Passweg J. Role of tumour angiogenesis in haematological malignancies. *Swiss Med Wkly* 2014; 144: w14050.
43. Medinger M, Passweg J. Angiogenesis in myeloproliferative neoplasms, new markers and future directions. *Memo* 2014; 7: 206-10.
44. Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. *Shock* 2007; 28: 4-14.
45. Verheul HM, Hoekman K, Luyckx-de Bakker S, Eekman CA, Folman CC, Broxterman HJ. Platelet: transporter of vascular endothelial growth factor. *Clin Cancer Res* 1997; 3: 2187-90.
46. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? *Clin Cancer Res* 2000; 6: 3147-52.
47. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. *Eur Respir J* 2008; 32: 1371-85.
48. Morrison LK, Harrison A, Krishnaswamy P, et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. *J Am Coll Cardiol* 2002; 39: 202-9.
49. Kanazawa H. Role of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. *Med Sci Monit* 2007; 13: RA189-195.